Immunotherapy has been unsuccessful in advanced solid tumors refractory to standard therapy, including PD-1 and CTLA-4, because of hostile tumor microenvironments. Thus, these types of patients with sarcomas and lung, ovarian, and gastrointestinal carcinomas represent a significant unmet need in this space.
Read more